**Table 1 :** Patients’ characteristics

|  |  |
| --- | --- |
|  |  Patient Population (n) |
| Age (median) | 56 (25-81) |
| Gender  | Females(n):57/ Males (n):98 |
| MMSubgroup | Heavy Chain (n): 116Light Chain (n): 32Non-secretory (n): 3Not evaluated (n):4 |
| ISS | ISS I(n): 40 ISS II(n): 49 ISS III(n): 41 Not evaluated (n): 25 |
| R-ISS | R-ISS I (n): 21R-ISS II (n): 60R-ISS III (n): 11Not evaluated (n): 63 |
| Durie Salmon | DS1(n): 5DS2(n):16DS3(n):129Not evaluated (n): 5 |
| Pre-transplantation response  | CR(n) : 58VGPR(n): 39 PR(n): 41Stable(n): 10 Refractory(n):3Not evaluated (n): 4 |
| Chemotherapy line(s) | 1 line (n): 502 lines (n): 903 lines (n): 94 line (n): 2Not evaluated (n):4 |
| Melphalan dose | 140mg/m2(n): 14200mg/m2(n): 141 |
| Renal failure(GFR<50 ml/min) | Present(n): 7None(n): 148 |
| Radiotherapy | Applied(n) : 21Not-applied(n):134 |
| Infused CD34+ cell (median) | 4.62 x106 /kg (2.4-13.4) |

*ISS: international staging system, R-ISS: revised-international staging system, CR: complete response, VGPR: very good partial response, PR: partial response, GFR: glomerular filtration rate,*

**Table 2:** The factors impacting OS

|  |  |  |
| --- | --- | --- |
|  | **PFS** | **OS** |
| **Gender** | 0.873 | 0.775 |
| **MM subtype** | 0.229 | 0.215 |
| **ISS** | 0.522 | 0.560 |
| **R-ISS**  | 0.339 | 0.033\* |
| **Durie Salmon stage** | 0.824 | 0.973 |
| **Chemoterapy line(s) received** | 0.252 | 0.707 |
| **Melphalan dose** | 0.607 | 0.795 |
| **Pre-transplantation response** | 0.066 | 0.846 |

*PFS: progression-free survival, OS: overall survival, ISS: international staging system, R-ISS: revised-international staging system*